Absorption, distribution and excretion of 14C-probimane in mice bearing lewis lung carcinoma

Scientia Pharmaceutica

Volumn 78, Issue 3, 2010, Pages 445-450

  Lu, Da Yong ^a,b   Chen, Rui Ting ^b   Lu, Ting Ren ^a   Wu, Hong Ying ^a   Qu, Rong Xin ^a   Che, Jin Yu ^a   Xu, Bin ^b  

^a SHANGHAI UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anti cancer agents; Bisdioxopiperazine compounds; Cancer chemotherapy; Drug distribution; Probimane

Indexed keywords

ANTIMETASTATIC AGENT; BISDIOXOPIPERAZINE; PROBIMANE; PROBIMANE CARBON 14; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; FECES; LEWIS CARCINOMA; LUNG METASTASIS; LUNG NODULE; MOUSE; NONHUMAN; RADIOACTIVITY;

EID: 77957362576     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1005-05     Document Type: Article

References (16)

1. Taraboletti G. Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol. 2001; 1: 378-384. doi:10.1016/S1471-4892(01)00065-0
2. Sava G, Bergamo A. Drug control of solid tumour metastases: a critical view. Anticancer Res. 1999; 19: 1117-1124. PMid:10368662
3. Lu DY, Huang M, Zhou J, Ding J. Recent advances in anti-metastatic drug development. Acta Pharmacol Sin. 2006; 27 (Suppl): 66-67.
4. Hellmann K, Burrage K. Control of malignant metastases by ICRF-159. Nature. 1969; 224: 273-275. doi:10.1038/224273a0
5. Herman EH, Witiak DT, Hellmann K, Waradek VS. Properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Adv Pharmacol Chemother. 1982; 19: 249-290. doi:10.1016/S1054-3589(08)60025-3
6. Ji RY. Probimane. Drugs Fut. 1988; 13: 418-419
7. Lu DY, Xu B, Ding J. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. BMC Pharmacol. 2004; 4: 32. doi:10.1186/1471-2210-4-32
8. Lu DY, Huang M, Xu CH, Yang WY, Hu CX, Lin LP, Tong LJ, Li MH, Lu W, Zhang XW, Ding J. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol. 2005; 5: 11. doi:10.1186/1471-2210-5-11
9. Lu DY, Huang M, Xu CH, Zhu H, Xu B, Ding J. Medicinal Chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines. Med Chem. 2006; 2: 369-375. doi:10.2174/157340606777724095
10. Salsbury AJ, Burrage K, Hellmann K. Histological analysis of the antimetastatic effect of (±)-1,2-bis(3,5-dioxopiperazin-1-yl) propane. Cancer Res. 1974; 34: 843-849. PMid:4814997
11. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res. 2000; 6: 4697-4704. PMid:11156222
12. Hellmann K. Dynamics of tumor angiogenesis: effect of razoxane- induced growth rate slowdown. Clin Exp Metastasis. 2003; 20: 95-102. doi:10.1023/A:1022632413888
13. Lu DY, Chi J, Lin LP, Huang M, Xu B, Ding J. Effect of anticancer drugs on the binding of 125I-fibrinogen to two leukaemia cell lines in vitro. J Int Med Res. 2004; 32: 488-491. PMid:15458280
14. Lu DY, Liang G, Zhang MJ, Xu B. Serum contents of sialic acids in mice bearing different tumors. Chin Sci Bull. 1994; 39: 1220-1223.
15. Lu DY, Wu FG, Shen ZM, Lu TR, Wu HY, Che JY, Xu B. Different spontaneous pulmonary metastasis inhibitions against Lewis lung carcinoma in mice by Bisdiopiperazine compounds of different treatment schedules. Sci Pharm, 2010; 78: 13-20. doi:10.3797/scipharm.0910-16
16. Greig N, Fang XC, Hellmann K. Razoxane penetration into the cerebrospinal fluid of rats. Cancer Chemother Pharmacol. 1982; 8: 251-252. PMid:7105386